Proteomics International Laboratories Ltd. ( (AU:PIQ) ) has issued an announcement.
Proteomics International Laboratories Ltd has launched Promarker®D, a predictive test for diabetic kidney disease, in Australia, coinciding with World Kidney Day. This test, which can predict the onset of chronic kidney disease up to four years in advance for diabetes patients, is expected to significantly impact healthcare by enabling early intervention and potentially reducing the incidence of kidney failure. The launch in Australia is part of a broader global commercialization strategy, with plans to expand into the USA and European markets, supported by a new laboratory in California.
More about Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd, based in Perth, Western Australia, is a medical technology company specializing in precision diagnostics and bio-analytical services. It is a pioneer in developing innovative diagnostic tests, including the Promarker® platform, which aims to provide early detection and management solutions for various diseases.
YTD Price Performance: -40.0%
Average Trading Volume: 164,919
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$62.88M
For detailed information about PIQ stock, go to TipRanks’ Stock Analysis page.